Oil Prices Keep Rising After Israel and Iran Hit Energy Infrastructure
Oil prices continued climbing Sunday after Israel and Iran traded blows against their respective energy facilities , threatening to expand the impact of the conflict into financial markets and the global economy.
Benchmark U.S. crude futures recently rose by more than 3%, to nearly $76 a barrel, following an even sharper increase in price on Friday. While Israeli strikes have yet to stall Iranian oil exports, analysts fear a worst-case scenario in which Tehran disrupts shipments through the Strait of Hormuz.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Rystad: Oil Prices To Remain Below $80 Despite Escalating Middle East Tensions
Oil prices are likely to remain capped below $80 per barrel despite the escalating Israel-Iran conflict, research firm Rystad Energy said on Monday, as Iran and Israel continue to trade strikes with the escalation now in its fourth day. 'Based on our earlier disruption simulations, we see oil prices capped below $80 per barrel,' Mukesh Sahdev, Rystad Energy's Global Head of Commodities Markets – Oil, said in a market update, carried by Africa Oil+Gas Report. The conflict appears likely to be contained and the United States could potentially play a central role, according to Sahdev. The worst fear in the market is a potential closure of the Strait of Hormuz, the world's most critical crude flow lane where more than 20 million barrels of crude pass every day—equal to a fifth of global daily oil consumption. While disruption to Strait of Hormuz flows could be devastating and would send oil prices spiking and add further tensions, it is an unlikely scenario for many observers and analysts, including those at Rystad Energy. 'A blockade remains the key risk that could push markets into uncharted territory,' Janiv Shah, Rystad Energy's Vice President, Commodities Markets – Oil, said. However, 'Given its interest in keeping prices closer to $50, the US could play a stabilizing role,' Shah added. 'We maintain our view that this is likely to remain a short-lived conflict, as further escalation risks spiraling beyond the control of key stakeholders,' Shan said. Despite Israel and Iran hitting each other's energy sites over the weekend, the targets are not material to global oil production or crude flows. Following the oil price jump on Friday after the start of the Israeli strikes on Iran, oil was muted in early trading on Monday, with both benchmarks falling by around 1% and trading in the low $70s per barrel as key oil flows from the Middle East remain unaffected. By Charles Kennedy for More Top Reads From this article on
Yahoo
32 minutes ago
- Yahoo
Oil prices fall and stocks rise, despite ongoing Israel-Iran conflict
Oil prices fell and stocks climbed on Monday, indicating optimism among investors about the limits of economic fallout from the ongoing Israel-Iran conflict. The Dow Jones Industrial Average jumped 361 points, or 0.8%, by midday erasing much of the losses suffered on Friday as back-and-forth strikes broke out between the two countries. The S&P 500 climbed 0.9% on Monday, while the tech-heavy Nasdaq increased 1.4% by midday. In each case, the gains erased nearly all of the losses suffered as the conflict began days earlier. MORE: Israel-Iran live updates: Israel claims 'full' aerial control over Tehran Oil prices, meanwhile, ticked slightly lower on Monday, easing a surge in prices set off late last week as investors feared a wider regional war in the oil-rich Middle East. The U.S. West Texas Intermediate futures price -- a key measure of U.S. oil prices -- dropped 1.8% on Monday. Brent crude future prices, another top measure of oil prices, also fell about 1.9%. Each index had climbed as much as 10% in the immediate aftermath of the conflict. Aerial attacks between Israel and Iran continued overnight into Monday, marking a fourth day of strikes following Israel's Friday attack. That surprise operation hit at the heart of Iran's nuclear program, striking key facilities and killing several nuclear scientists as well as high-ranking military leaders, according to Israeli officials. The U.S. did not provide any military assistance or have any involvement in Israel's Friday strikes, a U.S. official told ABC News. President Donald Trump told ABC News on Sunday, "It's possible we could get involved." The U.S. did provide assistance in shooting down incoming missile and drone attacks from Iran in response to Israel's initial barrage, officials said. The drop in oil prices may ease a potential uptick in the price of gasoline for U.S. drivers. Since crude oil makes up the top ingredient in car fuel, the Israel-Iran conflict threatened to modestly increase prices over the coming days and significantly hike them in the event of a wider war, experts previously told ABC News. MORE: Trump says 'it's possible' US gets involved in Israel-Iran conflict 'By later this week, we'll likely see nearly all states with price increases as retail gas prices rise following Iran/Israel attacks,' Patrick de Haan, the head of petroleum analysis at GasBuddy, said on Monday in a post on X. The move higher for U.S. stocks mirrored gains in markets across Asia and Europe. The STOXX Europe 600 index ticked up 0.3% by mid-afternoon local time. In Japan, the Nikkei 225 in Tokyo climbed 1.2% on Monday. ABC News' David Brennan contributed to this report.. Oil prices fall and stocks rise, despite ongoing Israel-Iran conflict originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Teva 2024 Healthy Future Report: Advancing Innovation and Collaboration
NORTHAMPTON, MA / / June 16, 2025 / Improving access to medicines and healthcare requires a continued effort to develop new evidence-based solutions that address unmet needs. We engage in scientific collaborations with universities and research centers, start-ups, pharmaceutical companies, hospitals and health maintenance organizations to find external scientific solutions for internal R&D needs. These efforts increase our scientific visibility, while expanding and accelerating our innovative medicines portfolio, in line with the Step-up Innovation pillar of our Pivot to Growth business strategy. Ultimately, these innovation efforts can shorten discovery and development timelines and increase success rates in discovering new drug candidates, as well as finding solutions to advance our pipeline. Innovation and Collaboration Initiatives Our approach to innovation is multi-directional, connecting internal needs (identified through meetings and workshops), with external opportunities (identified through deep mapping, our database, AI-based scouting and other conventional approaches). Participation and membership of key industry and trade associations enriches Teva's network across the industry in line with our strategic focus areas and, as a partner of choice in the biotech ecosystem, we provide access to industry insights and our team's expertise. In the USA, we have partnerships with key universities to foster innovation, including Harvard, Thomas Jefferson, Pittsburgh, Oklahoma and Pennsylvania. In Europe, we have been part of the Innovative Medicines Initiative (IMI) since 2019. It is Europe's largest public-private partnership in life sciences and aims to develop next-generation vaccines, medicines and treatments. In 2024 we participated in more than eight IMI consortia - from drug discovery to development. Two new consortia focused on biologics and biomarkers: RealHOPE: aims to develop guidelines for improving handling of biologic drugs from the user end (pharmacies and patients/ caregivers). European Platform for Neurodegenerative Diseases (EPND): intends to establish a platform for storing and analyzing clinical and biological samples and data for biomarker discovery in progressive loss of structure or function of neurons (neurodegeneration). A strategic focus in our global innovation and collaboration activities revolves around growing and leveraging the health ecosystem in Israel, given Teva's deep ties to the country, and historic successes that include academic collaborations. Our engagement approach in Israel re-started in 2020, and since then we have established approximately 50 projects with Israeli researchers; these have received 18 partnership grants to date from the Israel Innovation Authority, two of which were given additional advanced grant funding in 2024. Key initiatives in our Israel-focused collaboration include: AION Labs: An alliance between Teva and three other global pharmaceutical companies, Amazon and the Israel Biotech Fund, AION creates and supports start-ups focusing on artificial intelligence (AI) in drug discovery and development. We play an active role in AION Labs, supporting with training and engagement. AION has created eight new start-up partnerships and plans to establish two more in 2025. In 2024 we partnered to establish CombinAble, an AION start-up, which focuses on antibody optimization. We also supported Celleryx, a start-up focused on AI early diagnostics of cancer and autoimmune diseases based on cell states. Organospheres: We work with multiple start-ups, pharma companies and academic groups through Organospheres, a consortium that is developing a human ex-vivo 3D system that could provide an alternative to animals being used in preclinical studies. BioInnovators Forum: Each year we offer 30 specialist PhD and post-doctorate students mentorship and training on translational research, and an annual innovation competition for students to develop solutions to unmet medical needs. Since 2020 the program has attracted over 150 graduates since inception, leveraging the skills of young scientists to drive future medical innovation. In 2024, entries included an at-home detection kit for tuberculosis based on breathing molecular analysis, and an IVF support device for the fertilization and implantation of embryos. This program has also been a source for identifying scientific talent to bolster our R&D function. Since 2020: 50 innovation projects with Israeli researchers 18 partnership grants received from Israel Innovation Authority 150 graduates taken part in BioInnovators Forum Public Health Research We collect and use public health and epidemiological data to estimate unmet economic, clinical and social needs of patients across our key TAs, including central nervous system, psychiatric, inflammatory and oncological conditions. Our research focuses on understanding the burden of illness, examining new clinical educational tools and evaluating ways to ensure patients have access to necessary treatments and enable HCPs, payers and other decision-makers to focus on areas with the greatest need. We can also identify appropriate patient populations and design clinical trials with relevant inclusion and exclusion criteria to benefit the maximum number of patients with unmet needs. In 2024, we presented our research at 176 congresses and published 55 peer-reviewed articles across scientific and medical journals. Teva Research and Development Academic Papers Published on PubMed in 2024 (55 total) 33% Research Innovation 29% Neurology/Psychiatry 5% Immunology 11% Migraine 4% Central Nervous System/Pain 7% Oncology 4% Cardiovascular 7% Respiratory To learn more, read the full 2024 Healthy Future the full 2024 Healthy Future Report Disclosures. View additional multimedia and more ESG storytelling from Teva Pharmaceutical on Contact Info:Spokesperson: Teva PharmaceuticalWebsite: info@ SOURCE: Teva Pharmaceutical View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
